IONS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ionis Pharmaceuticals Inc is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as upcoming data presentations and favorable analyst ratings, the technical indicators are weak, and the financial performance shows declining revenue and persistent losses. Additionally, insider selling and the lack of significant trading signals from Intellectia Proprietary Trading Signals suggest caution. The stock may be worth monitoring for future developments but does not present a compelling entry point right now.
The MACD is negatively expanding (-0.825), indicating bearish momentum. RSI is at 22.639, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. The stock is trading below the pivot point (80.284) and is closer to the support level (S1: 76.005, S2: 73.362), suggesting limited upside in the short term.
Ionis Pharmaceuticals is presenting new data for DAWNZERA at the AAAAI Annual Meeting, highlighting its clinical value for hereditary angioedema. Analysts have raised price targets recently, with several maintaining Overweight or Buy ratings. Hedge funds are increasing their positions, with a 242.57% rise in buying activity over the last quarter.
Insiders are selling shares, with a 255.74% increase in selling activity over the last month. The company's revenue guidance for 2026 is below consensus expectations, and financial performance in Q4 2025 showed a 10.26% YoY revenue decline. Technical indicators suggest bearish momentum, and no significant Intellectia Proprietary Trading Signals are present.
In Q4 2025, revenue dropped by 10.26% YoY to $203.33M. Net income improved to -$229.39M, up 119.83% YoY, while EPS increased to -1.41, up 113.64% YoY. Gross margin declined slightly to 96.09%, down 2.26% YoY. Overall, the financials show mixed results with declining revenue but improving net income and EPS.
Analysts are generally positive on Ionis Pharmaceuticals. Piper Sandler, Needham, and Wells Fargo have raised price targets, with some projecting targets as high as $103. Barclays and RBC Capital have also expressed optimism about the company's future, citing strong catalysts and a favorable risk/reward profile. However, Stifel maintains a Hold rating, reflecting some caution.
